Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.49 |
| ▸ | CTSL | P07711 | 6/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763315 | 1.00 | CTSK (0.49) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4891128 | 0.93 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4891133 | 0.93 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4891126 | 0.93 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5092565 | 0.84 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5092560 | 0.84 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5105552 | 0.83 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4770250 | 0.80 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4768473 | 0.80 | CTSK (0.76) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4048060 | 0.80 | CTSK (0.59) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CTSK 47/4885CTSL 20/4885CTSS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.